It was approved in 2023 for adult patients with R/R MM who have undergone at least four prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 mAb, showing promising results in clinical trials [95]. This evidence concerns the gene CD38 and Miyoshi myopathy.